drugset
drugset / Trial / NCT07226206

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

NCT07226206 ↗

Phase 1/2 Recruiting 5 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.

Timeline

Start
2026-07-14
Primary completion
2031-07-31
Completion
2031-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SPK-8011QQ Unknown — Intravenous

Indications

hemophilia A